Table 2.
Treatment, complications, and outcomes of COVID-19 patients.
| Variables (n [%] or median [IQR]) | All patients (n = 309) | Non-corticosteroid (n = 220) | Corticosteroid (n = 89) | P value |
|---|---|---|---|---|
| Drug treatment | ||||
| Atomized inhalation of interferon α-2b | 179 (57.9) | 120 (54.5) | 59 (66.3) | 0.058 |
| Lopinavir-ritonavir | 231 (74.8) | 151 (68.6) | 80 (89.9) | <0.001 |
| Arbidol | 142 (46.0) | 99 (45.0) | 43 (48.3) | 0.597 |
| Complications | ||||
| Respiratory failure | 26 (8.4) | 3 (1.4) | 23 (25.8) | <0.001 |
| ARDS | 4 (1.3) | 0 | 4 (4.5) | 0.002 |
| Outcomes | ||||
| Severe illness | 35 (11.3) | 4 (1.8) | 31 (34.8) | <0.001 |
| Admission to ICU | 20 (6.5) | 2 (0.9) | 18 (20.2) | <0.001 |
| Death | 0 | 0 | 0 | – |
| Day of negative PCR from symptom onset | 17.0 (13.0, 20.0) | 16.0 (13.0, 19.0) | 18.0 (15.0, 23.0) | <0.001 |
| Discharged | 236 (76.4) | 167 (75.9) | 69 (77.5) | 0.762 |
| Day of hospitalization (days) | 15.0 (12.0, 20.0) | 15.0 (12.0, 19.0) | 17.0 (14.0, 23.0) | <0.001 |
IQR, interquartile range; ICU, Intensive care unit; PCR, polymerase chain reaction.